Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Aniracetam and Lemairamin — mechanism, side effects, legal status, and pricing.
Aniracetam is a non-peptide pyrrolidinone derivative and positive allosteric modulator of AMPA-type glutamate receptors. It is marketed as a prescription drug for cognitive disorders in some European countries (Italy, Greece) but has never been approved by the US FDA as either a drug or dietary supplement ingredient. The compound was reportedly withdrawn from the Japanese market following a failed confirmatory trial. Despite lacking US regulatory approval, aniracetam is openly sold online by nootropic-supplement retailers, often with significant label-accuracy problems.
Lemairamin is a non-peptide small-molecule cinnamamide alkaloid (N-phenethyl cinnamide) natural product, not approved for human use in any jurisdiction. All available data are preclinical (rodent, zebrafish, C. elegans, in vitro, and computational). It is sold exclusively as an unregulated 'research chemical' explicitly labeled 'not for human consumption'; quality, purity, and identity are not independently verified by any regulatory body. No human clinical trials, pharmacokinetic studies, or safety data exist.
Aniracetam
Lemairamin
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Aniracetam
No pricing data yet.
Check Aniracetam prices →Lemairamin
No pricing data yet.
Check Lemairamin prices →COA corpus from Disclosed Labs — independently tested batches only.
Aniracetam
2
COAs
99.5%
Avg purity
2
Labs
Lemairamin
2
COAs
99.8%
Avg purity
2
Labs
The principal human efficacy evidence is one 6-month, double-blind, placebo-controlled multicenter trial in 109 elderly patients meeting probable-Alzheimer's criteria, which showed significant improvement in psychobehavioral parameters versus placebo with excellent reported tolerability, though no itemized adverse-event breakdown was available. No long-term (multi-year) human safety data were located, and no interventional trials of aniracetam are currently registered on ClinicalTrials.gov. In rodent models, aniracetam (50 mg/kg/day for 10 postnatal days) reversed prenatal-ethanol-induced avoidance-learning deficits in rat offspring and increased AMPA-receptor-mediated synaptic currents in hippocampal CA1 pyramidal cells. However, oral aniracetam (50 mg/kg, 5 days/week for 6 weeks) produced no cognitive or behavioral enhancement in healthy adult C57BL/6J mice across a comprehensive test battery.
Key references
No human data exist. No completed or registered human clinical trials were located on ClinicalTrials.gov, and no PubMed-indexed human pharmacokinetic, safety, or efficacy studies exist. All available data are preclinical: In transgenic Alzheimer's mice, gx-50 disassembled Aβ oligomers, decreased cortical Aβ accumulation, inhibited Aβ-induced neuronal apoptosis and calcium toxicity, improved Morris water maze performance, and was reported to cross the blood-brain barrier (Tang et al. 2013). In mouse and rat pain models (formalin tonic, neuropathic, bone-cancer pain), subcutaneous and intrathecal lemairamin dose-dependently reduced pain hypersensitivity/mechanical allodynia without evident tolerance, linked to spinal α7 nAChR activation and downstream IL-10/β-endorphin release (Wang et al. 2020). Murine microglial cell cultures showed gx-50 activation of α7 nAChR engaged JAK2/STAT3 and PI3K/AKT signaling to suppress pro-inflammatory cytokine secretion (Shi et al. 2016). Zebrafish DSS-induced colitis models showed lemairamin attenuated intestinal inflammation via Akt signaling (2024). C. elegans studies reported WGX-50 promoted markers of healthy ageing (daf-16/skn-1 longevity genes, 2025).
Aniracetam and Lemairamin are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Key references
Disclosed Labs